Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 2024-08-27 AGM Information
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting
AGM Information Classification · 1% confidence The document is a press release announcing that the shareholders of MorphoSys AG approved all resolutions at its 2024 Annual General Meeting (AGM), specifically mentioning the 'Merger Squeeze-Out'. The key phrase is '2024 Annual General Meeting' and the content relates directly to the proceedings and outcomes of that meeting. This aligns perfectly with the definition of AGM Information (AGM-R). Although it discusses a merger outcome, the context is the approval at the meeting itself, not the M&A proposal (TAR) or the voting results (DVA), as it is a general announcement about the meeting's success.
2024-08-27 English
MorphoSys Completes Voluntary Delisting from the Frankfurt Stock Exchange and Nasdaq Global Market
Delisting Announcement Classification · 1% confidence The document is a corporate news release dated August 5, 2024, announcing that MorphoSys has completed the voluntary delisting of its shares from the Frankfurt Stock Exchange and its ADSs from the Nasdaq Global Market. The key phrase in the document is "MorphoSys Completes Voluntary Delisting from the Frankfurt Stock Exchange and Nasdaq Global Market," and the keyword listed is "Delisting." This directly corresponds to the definition for Delisting Announcement (DLST). The document length (7780 chars) is substantial enough that it is the announcement itself, not just a brief notice of publication.
2024-08-05 English
MorphoSys AG: Korrektur: Bekanntmachung der Einberufung zur Hauptversammlung am 27.08.2024 in Planegg mit dem Ziel der europaweiten Verbreitung gema 121 AktG
AGM Information Classification · 1% confidence The document is explicitly titled 'Einladung zur ordentlichen virtuellen Hauptversammlung 2024 der MorphoSys AG' (Invitation to the Annual General Meeting 2024 of MorphoSys AG) and details the agenda (Tagesordnung) for this meeting, including voting on the discharge of management/supervisory boards, election of the auditor, and election of supervisory board members. This content is characteristic of materials distributed to shareholders in advance of an Annual General Meeting (AGM). While it contains references to the Annual Report (Jahresabschluss) under Agenda Item 1, the document itself is the formal invitation and notice for the meeting, which aligns best with the AGM Information category (AGM-R). It is not the full 10-K, nor is it a general proxy statement (DEF 14A/PSI), but specifically the notice for the AGM.
2024-07-19 German
MorphoSys AG: Bekanntmachung der Einberufung zur Hauptversammlung am 27.08.2024 in Planegg mit dem Ziel der europaweiten Verbreitung gema 121 AktG
AGM Information Classification · 1% confidence The document is explicitly titled 'Bekanntmachung der Einberufung zur Hauptversammlung' (Announcement of the Convocation to the General Meeting) and repeatedly refers to the 'ordentlichen virtuellen Hauptversammlung 2024' (Ordinary Virtual General Meeting 2024) scheduled for August 27, 2024. The text details the agenda (Tagesordnung), which includes voting on the approval of financial statements, discharge of management/supervisory boards, election of auditors, and election/reduction of the supervisory board size. This content perfectly matches the definition of materials shared during an Annual General Meeting (AGM). Therefore, the classification is AGM-R.
2024-07-19 German
Declaration of Voting Results & Voting Rights Announcements 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is explicitly titled 'Voting Rights Announcements' and details a notification pursuant to Section 43 (1) WpHG (German Securities Trading Act) regarding Novartis AG's share of voting rights in MorphoSys AG exceeding the 75% threshold. This directly corresponds to the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA), which covers official results from shareholder votes or significant changes in voting power.
2024-07-18 English
MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market
Delisting Announcement Classification · 1% confidence The document is a news release titled "MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market." It explicitly states the intention to voluntarily delist ADSs from Nasdaq and deregister them under the Exchange Act, mentioning the filing of Form 25. This content directly corresponds to the definition of a Delisting Announcement (DLST). Although it mentions the upcoming merger squeeze-out, the primary, immediate action announced is the delisting.
2024-07-12 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.